Cell line · CVCL_0079
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| ETV6 Rearrangement Suppresses CDKN1B Transcription by Disrupting an Intragenic Super-enhancer in Acute Lymphoblastic Leukemia. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel immunotherapeutics against LGR5 to target multiple cancer types. | EMBO Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| An Alternatively Spliced Gain-of-Function NT5C2 Isoform Contributes to Chemoresistance in Acute Lymphoblastic Leukemia. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting pediatric cancers via T-cell recognition of the monomorphic MHC class I-related protein MR1. | J Immunother Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. | Cell Genom | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Functional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR+ Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. | Nat Commun | 2022 | Cellosaurus cites it | PubMed | |
| Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. | J Steroid Biochem Mol Biol | 2022 | Cellosaurus cites it | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy. | Cancer Med | 2019 | Cellosaurus cites it | PubMed | |
| The LL-100 panel: 100 cell lines for blood cancer studies. | Sci Rep | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0079/papers